CRIS Current Research Information System

AMBROSINI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.642
EU - Europa 5.714
AS - Asia 3.686
AF - Africa 354
SA - Sud America 21
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 18.427
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.616
GB - Regno Unito 1.925
CN - Cina 1.219
VN - Vietnam 1.159
SG - Singapore 813
DE - Germania 792
IT - Italia 731
SE - Svezia 632
IN - India 346
UA - Ucraina 346
RU - Federazione Russa 264
IE - Irlanda 259
FR - Francia 234
ZA - Sudafrica 129
EE - Estonia 119
CH - Svizzera 106
TG - Togo 97
FI - Finlandia 79
CI - Costa d'Avorio 61
JO - Giordania 47
BG - Bulgaria 46
BE - Belgio 37
NG - Nigeria 37
AT - Austria 30
GR - Grecia 24
SC - Seychelles 24
IR - Iran 23
ES - Italia 20
NL - Olanda 19
TR - Turchia 18
CA - Canada 15
HK - Hong Kong 14
HR - Croazia 13
ID - Indonesia 13
BR - Brasile 11
JP - Giappone 8
LB - Libano 8
MX - Messico 7
PL - Polonia 7
AU - Australia 6
CZ - Repubblica Ceca 6
TW - Taiwan 6
DK - Danimarca 4
RO - Romania 4
BJ - Benin 3
CO - Colombia 3
MD - Moldavia 3
SM - San Marino 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AR - Argentina 2
CL - Cile 2
EU - Europa 2
HU - Ungheria 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
PK - Pakistan 2
PT - Portogallo 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
JM - Giamaica 1
KR - Corea 1
KW - Kuwait 1
LU - Lussemburgo 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TN - Tunisia 1
Totale 18.427
Salva come PNG Salva come JPEG
Città #
Southend 1.798
Fairfield 1.160
Chandler 735
Singapore 712
Ashburn 624
Woodbridge 543
Houston 505
Seattle 504
Wilmington 476
Princeton 407
Cambridge 384
Dong Ket 384
Santa Clara 288
Ann Arbor 276
Dublin 259
Boardman 246
Jacksonville 216
Nanjing 167
Westminster 160
Bologna 151
Padova 144
Berlin 111
Lomé 97
Bern 96
Jinan 89
Beijing 83
Shenyang 80
Saint Petersburg 76
New York 71
Helsinki 70
Hebei 66
Redmond 62
Abidjan 61
Medford 56
Changsha 51
Mülheim 51
San Diego 50
Guangzhou 49
Nanchang 49
Milan 48
Amman 47
Turin 45
Bremen 44
Tianjin 43
Sofia 39
Abeokuta 35
Dearborn 33
Zhengzhou 33
Jiaxing 31
Redwood City 30
Los Angeles 29
Shanghai 29
Brussels 28
Des Moines 28
Florence 26
Falls Church 24
Haikou 23
Hangzhou 23
Mahé 23
Vienna 21
Kuban 20
Olalla 20
Norwalk 19
Kunming 18
Taizhou 18
Taiyuan 16
Ningbo 15
Falkenstein 13
Jakarta 13
San Venanzo 13
Shenzhen 13
Frankfurt am Main 12
Lanzhou 12
Mountain View 12
Paris 12
Verona 12
Wuhan 12
Bühl 10
Costa Mesa 10
Fuzhou 10
Hefei 10
Istanbul 10
Rome 10
Calderara di Reno 9
Chicago 9
Frankfurt Am Main 9
Hong Kong 9
London 9
Moscow 9
Naples 9
Buffalo 8
Lappeenranta 8
Phoenix 8
Pune 8
São Paulo 8
Toronto 8
Breda 7
Foshan 7
Genzano Di Roma 7
Cesena 6
Totale 12.537
Salva come PNG Salva come JPEG
Nome #
(18)F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. 187
18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. 179
18F-FDG PET/CT in visceral leishmaniasis: uptake patterns in the context of a multiannual outbreak in Northern Italy 174
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors. 173
18F-FACBC Compared With 11C-Choline PET/CT in Patients With Biochemical Relapse After Radical Prostatectomy: A Prospective Study in 28 Patients. 173
A [68Ga]Ga-DOTANOC PET/CT radiomic model for non-invasive prediction of tumour grade in pancreatic neuroendocrine tumours 173
Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study 172
68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. 169
(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. 169
Comparing PET-derived semiquantitative parameters and radiomic features in discriminating G1 and G2 primary pancreatic neuroendocrine tumours in 68Ga-DOTANOC PET/CT 169
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 168
Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy 163
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 161
Radiomic analysis performed on 68Ga-DOTANOC PET/CT allows discriminating primary pancreatic neuroendocrine tumour grading 161
18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin 160
(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. 159
18F-FDG PET/CT detects systemic involvement in Sarcoidosis 158
68Ga-DOTATATE PET/CT interobserver agreement for neuroendocrine tumor assessment: Results of a prospective study on 50 patients 157
68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease. 155
68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma 153
F-18 FDG PET/CT detects muscle involvement in Erdheim-Chester disease 149
18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis: Results of a Preliminary Prospective Study 148
Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience 147
Comparison between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. 144
The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. 144
68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. 143
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. 140
68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. 139
Evaluation of unusual neuroendocrine tumours by means of (68)Ga-DOTA-NOC PET. 137
Assessment of a chemically induced model of lung squamous cell carcinoma in mice by 18F-FDG small-animal PET. 137
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 136
18f-fdg pet/ct for restaging gastric cancer after surgical resection 132
Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). 132
(18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. 129
68Ga DOTANOC PET/CT Detects Primary Malignant Insulinoma. 129
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 128
11C-Choline PET/CT in patients with biochemical relapse after radical prostatectomy and PSA levels < 0.5 ng/mL 127
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 127
Colon Sarcoidosis Mimicking Cancer at 18F-FDG PET/CT 125
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 123
Cardiac FDG PET/CT to Assess the Culprit Lesion during Acute Infarction 122
A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience 121
Radiomic analysis could allow detecting misassigned bioptic grading when discriminating G1 and G2 primary pancreatic neuroendocrine tumours imaged with 68Ga-DOTANOC PET/CT 121
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results 120
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 117
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 117
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. 117
Analisi in vitro ed in vivo dell'attività anti-tumorale dopo inibizione specifica di MYCN mediante PNA-NLS anti-gene nel rabdomiosarcoma umano 116
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 116
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma 116
Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Review 116
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. 115
A new dimension of FDG-PET interpretation: assessment of tumor biology. 115
Histopathological diagnosis of appendiceal neuroendocrine neoplasms: when to perform a right hemicolectomy? A systematic review and meta-analysis 115
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. 114
Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. 114
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models. 114
18F-FDG PET/CT impact on testicular tumours clinical management 113
Merkel cell carcinoma: a prompt diagnosis to increase survival 113
Focal lung uptake of 18F-fluorodeoxyglucose (18F-FDG) without computed tomography findings. 112
Incidental finding of an (11)C-choline PET-positive solitary plasmacytoma lesion. 112
(68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. 112
Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma 110
Small animal PET for the evaluation of an animal model of genital infection 110
Is there an ideal diagnostic algorithm in solitary pulmonary nodules? 109
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. 109
Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature 108
The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? 108
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 107
Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF 107
FDG small animal PET permits early detection of malignant cells in a xenograft murine model. 106
Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis 106
G1/G2 discrimination of pNET with [68Ga]Ga-DOTANOC PET/CT quantitative parameters: is it feasible? 106
68Ga-DOTA-NOC PET and CT retrospective analysis for neuroendocrine bone metastasis detection 105
Ga-68-DOTA-peptides versus F-18-DOPA PET for the assessment of NET patients 103
Validation of the 2010 WHO classification and a new prognostic proposal: A single centre retrospective study of well-differentiated pancreatic neuroendocrine tumours 103
Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? 102
Preliminary results of the Italian FOLCETUX study: early evaluation of treatment response with 18FDG PET in gastric or gastroesophageal junction adenocarcinoma. 101
Performance evaluation of a small animal PET scanner. Spatial resolution characterization using F-18 and C-11. 101
Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report 101
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. 100
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis 99
Pitfalls in oncology: Osteoblastic response mimicking bone progression during ceritinib treatment in ALK-rearranged NSCLC 99
Treatment of advanced gastro‐entero‐pancreatic neuro‐ endocrine tumors: A systematic review and network meta‐analysis of phase iii randomized controlled trials 99
Case Report: The Complete Remission of a Mixed Germ Cell Tumor With Somatic Type Malignancy of Sarcoma Type With a GCT-Oriented Therapy: Clinical Findings and Genomic Profiling 99
Small animal PET in oncology: the road from bench to bedside. 98
Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review 97
Molecular Imaging with Small Animal PET/CT 96
Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice 96
Neuroendocrine Tumours Pictorial Atlas 96
Incidental diagnosis of very small rectal neuroendocrine neoplasms: when should endoscopic submucosal dissection be performed? A single ENETS centre experience 96
68Ga-DOTA-NOC and 18F-DOPA PET in the evaluation of patients with neuroendocrine tumours. 95
Positron-emission tomography in gynaecologic malignancies. 95
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma 95
Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? 94
Neuroendocrine Tumours with Secondary Liver Lesions 93
68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level. 93
Lung cancer associated with cystic airspaces 93
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 92
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management 91
Totale 12.415
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.671
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.526 0 0 0 0 0 0 563 589 562 326 201 285
2020/20212.586 485 147 64 92 36 86 44 249 297 137 170 779
2021/20223.781 846 112 204 222 298 178 55 252 140 138 818 518
2022/20233.481 385 509 207 435 211 245 100 183 563 189 265 189
2023/2024885 96 159 40 77 72 167 53 56 34 61 35 35
2024/20252.232 144 648 350 254 626 210 0 0 0 0 0 0
Totale 18.837